RxDoctor Payments Data

Nina Khachiyants, MD

Behavioral Neurology & Neuropsychiatry · Manassas, VANPI 1376706887

Payments from drug & device makers

$1,579in general payments, 2019–2025

Across 71 payments — averaging $22.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$288
  • Johnson & Johnson$242
  • AbbVie$226
  • Otsuka America Pharmaceutical, Inc.$201
  • Ironshore Pharmaceuticals Inc.$192
  • Teva Pharmaceuticals USA, Inc.$101
  • plus $328 from 9 others

What the payments were for

  • Food & beverage$1,579100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few behavioral neurology & neuropsychiatry providers in Virginiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$22,973
Medicare patients
62
Services billed
266

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate87$214,066
Abilify MaintenaAripiprazole40$103,571
Risperdal ConstaRisperidone Microspheres13$29,290
VraylarCariprazine Hcl15$20,851
ZyprexaOlanzapine13$12,122
Lurasidone Hcl26$9,029
Olanzapine242$8,686
Aripiprazole107$8,159
Paliperidone ErPaliperidone27$6,452
Clozapine OdtClozapine13$6,438
Trazodone Hcl318$4,274
Risperidone301$3,782
Divalproex Sodium ErDivalproex Sodium121$3,146
Atomoxetine Hcl30$3,097
Fluphenazine Hcl33$2,920

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal Consta$242$243,356100 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$201$103,57140 claims
AbbVieVraylar$226$20,85115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few behavioral neurology & neuropsychiatry providers in Virginiaon file to place this against a meaningful peer group, so we don't.

Other behavioral neurology & neuropsychiatry in Manassas

Where these figures come from

Is this you, or does something look wrong? →